Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01986556 · ClinicalTrials.gov registry record · Phase 1
Lesinurad Tablet Relative Bioavailability
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01986556 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 36 participants.
The verdict
NCT01986556, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study will assess the relative bioavailability of lesinurad tablets, manufactured at two different sites.
Interventions
- DRUG Lesinurad 400 mg (Site 1)
- DRUG Lesinurad 400 mg (Site 2, Lot A)
- DRUG Lesinurad 400 mg (Site 2, Lot B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01986556
The ClinicalTrials.gov registry entry for NCT01986556 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lesinurad 400 mg (Site 1) is the first listed.
NCT01986556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01986556 about?
NCT01986556 is a clinical study titled "Lesinurad Tablet Relative Bioavailability". This study will assess the relative bioavailability of lesinurad tablets, manufactured at two different sites.
What is the current status of trial NCT01986556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-11. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01986556?
The interventions under investigation include: Lesinurad 400 mg (Site 1) (DRUG), Lesinurad 400 mg (Site 2, Lot A) (DRUG), Lesinurad 400 mg (Site 2, Lot B) (DRUG).
Who is sponsoring clinical trial NCT01986556?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.